Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pharvaris N.V.
(NQ:
PHVS
)
20.35
-1.36 (-6.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pharvaris N.V.
< Previous
1
2
Next >
Pharvaris Announces $70 Million Private Placement Financing
June 20, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
June 10, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Annual Meeting of Shareholders
June 01, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update
May 08, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop
May 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
April 05, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC
March 18, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present in Upcoming March Investor Conferences
March 02, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting
February 24, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present at SVB Securities Global Biopharma Conference
February 08, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Provides Regulatory, Clinical, and Corporate Updates
January 09, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update
December 08, 2022
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks
December 08, 2022
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022
November 10, 2022
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop
October 07, 2022
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer
September 30, 2022
From
Pharvaris N.V.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.